Compare GFR & LBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GFR | LBRX |
|---|---|---|
| Founded | 2018 | 2015 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 602.6M |
| IPO Year | N/A | 2025 |
| Metric | GFR | LBRX |
|---|---|---|
| Price | $5.78 | $23.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $49.00 |
| AVG Volume (30 Days) | 73.6K | ★ 180.8K |
| Earning Date | 03-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 252.40 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $470,838,329.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.81 | $13.36 |
| 52 Week High | $6.67 | $24.95 |
| Indicator | GFR | LBRX |
|---|---|---|
| Relative Strength Index (RSI) | 59.17 | 55.09 |
| Support Level | $5.66 | $23.52 |
| Resistance Level | $6.12 | $24.84 |
| Average True Range (ATR) | 0.28 | 1.52 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 66.67 | 64.14 |
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.
LB Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. It is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the company believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries.